INTRODUCTION
============

Tuberculosis (TB) has been one of the most significant infections causing human disease. In tropical countries, TB remains a leading cause of death. Poverty, overpopulation, inattention to tubercular services, and as a result of the human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (HIV/AIDS) epidemic there are more cases of TB today than at any previous time in human history.^\[[@b1-jtim-2015-0017]\]^ Following its advent HIV/AIDS relentlessly spread around the world with no signs of regression.^\[[@b2-jtim-2015-0017]\]^ In 1993, World Health Organization (WHO) declared TB a "global emergency." In our country, the overall prevalence of HIV is \<1% and India continues to be in the category of low prevalence countries. However, this statistic blurs the actual picture of the pandemic in our populous country. In the year 2011, 2.71 million people were estimated to be infected with HIV in India.^\[[@b2-jtim-2015-0017]\]^ The other major problem that threatens the TB control is the emergence of multi-drug resistant tuberculosis.^\[[@b1-jtim-2015-0017],[@b3-jtim-2015-0017]\]^ The immunosuppression as a result of HIV infection activates the latent TB infection and those infected spreading the bacilli in families, communities and health care settings significantly undermining TB control programs.^\[[@b4-jtim-2015-0017],[@b5-jtim-2015-0017]\]^

Goals for TB include a worldwide cure rate of 85% and a case detection rate of 70% by 2015. Goals for HIV include treating 3 million people with HIV infection in developing countries with antiretroviral drugs by 2015. The Millennium Development Goals include targets for improved child health and survival and for improved control of priority communicable diseases (including TB and HIV) by 2015. Progress in improving TB/HIV clinical care will contribute to achieving these goals. Clinicians have a vital contribution to make, not only to the clinical care of patients, but also to public health.^\[[@b6-jtim-2015-0017]\]^ Hence, we have undertaken this study to determine the seroprevalence of HIV infection among TB patients and to compare the clinical features of TB in HIV seropositive and seronegative patients.

MATERIALS AND METHODS
=====================

This was a prospective cohort study consisting 100 TB patients on outpatient department basis and inpatients admitted to VIIMS, Bellary from December 2010 to June 2012. The study protocol was approved by institutional ethics committee. The patients diagnosed with TB as per the case definitions of the Revised National Tuberculosis Control Program (RNTCP) and willing to give informed written consent were included in the study.^\[[@b7-jtim-2015-0017]\]^ Detailed history regarding the illness was recorded. A thorough physical examination of all the systems was carried out. Appropriate laboratory and radiological investigations were done as required pertaining to each case.

All the patients were screened for HIV after counseling. Serum samples were screened for HIV using Comb AIDS test of Pareeksha, a reagent kit evaluated and recognized by WHO. All reactive samples were subjected to TRILINE and TRI SPOT test confirmation of HIV. As per WHO guidelines, when the HIV reactive sample in the screening test is further subjected to supplemental tests and again found to be HIV reactive, the positive predictive value of the same is 99.99%.^\[[@b8-jtim-2015-0017]\]^ These cases were taken as HIV positive. All patients were assigned categories as per the RNTCP.^\[[@b7-jtim-2015-0017]\]^ Category I - (i) new sputum smear-positive (ii) new sputum smear-negative (iii) New extrapulmonary. Category II - (i) sputum smear-positive relapse (ii) sputum smear-positive failure (iii) sputum smear-positive treatment after default.

History, examination, investigations, and diagnosis were recorded in the form of a proforma.

Statistical analysis
--------------------

The statistical software SPSS 11.0 and Systat 8.0 were used for the analysis of the data. The Chi-square and Fisher exact test have been used to find the significance of proportions of various Demographic characteristics, symptoms, signs, Chest X-ray findings, and Diagnostic categories. The odds ratio (OR) has been computed to find the relationship of above-mentioned variables for seroprevalence. Student's *t*-test to find the significance difference of means for the body mass index (BMI), hemoglobin (Hb) percentage, and total count between seropositive and seronegative TB patients.

RESULTS
=======

A total of 100 patients, 81 males and 19 females diagnosed with TB were taken for the study. Of them, eight were seropositive, giving an overall seroprevalence of HIV among all forms of TB as 8%. The patients in the age group 21--30 2.02 (OR) times more likely to be seropositive with *P* = 0.394 and the patients in the age group of 31--40 are 11.11 (OR) times more likely to be seropositive with *P* = 0.003 compared to other age groups as shown in [Table 1](#t1-jtim-2015-0017){ref-type="table"}.

[Table 2](#t2-jtim-2015-0017){ref-type="table"} shows male TB patients are 1.70 (OR) times more likely to be seropositive compared to female TB patients but are not statistically significant.

Agriculturist TB patients are 2.68 (OR) times more likely to be seropositive with *P* = 0.225 and drivers among the TB patients are 4.57 (OR) times more likely to be seropositive compared to other occupation *P* = 0.287 and the TB patients in service category are 2.05 (OR) times more likely to be seropositive with *P* = 0.453 as shown in [Table 3](#t3-jtim-2015-0017){ref-type="table"}.

TB patients in the urban area are 2.28 (OR) more likely to be seropositive compared to the rural area with *P* = 0.264. Seroprevalence in not statistically associated with the marital status or past history of TB (*P* \> 0.05). The association of symptoms with seroprevalence in TB patients is shown in [Table 4](#t4-jtim-2015-0017){ref-type="table"} and association with signs shown in [Table 5](#t5-jtim-2015-0017){ref-type="table"}.

[Table 6](#t6-jtim-2015-0017){ref-type="table"} shows the association of chest X-ray with seroprevalence in TB patients. [Table 7](#t7-jtim-2015-0017){ref-type="table"} shows an association of diagnosis with seroprevalence in TB patients.

DISCUSSION
==========

A total of 100 patients, 81 male and 19 female diagnosed with TB were included in the study. The seroprevalence of HIV among all forms of TB was 8%. Our study found that seroprevalence rates among men were 8.64%, women 5.26% and was highest in the age group between 31 and 40 years at 29.41% \[[Tables 1](#t1-jtim-2015-0017){ref-type="table"} and [2](#t2-jtim-2015-0017){ref-type="table"}\] and had a significant association with seroprevalence (OR = 11.11, *P* = 0.003). Among the occupations \[[Table 3](#t3-jtim-2015-0017){ref-type="table"}\], seroprevalence was highest among drivers at 25%. However, most of the seropositive patients were from the agricultural background accounting for half the cases. The number of seropositive cases was equally distributed between urban and rural regions. Seroprevalence was found to be higher among the urban group of patients at 12.5% when compared to 5.88% among the rural group. Seroprevalence was 8.33% and 6.67% among the married and single patients, respectively. Patients with no previous history of TB had a seroprevalence of 8.86% whereas among patients with the previous history of the disease only 4.76% were seropositive (*P* \> 0.05).

Patients presented with various symptoms \[[Table 5](#t5-jtim-2015-0017){ref-type="table"}\] though 81% of patients complained of cough only 3.7% of those patients were seropositive (OR = 0.11, *P* = 0.006). This can be explained by the fact that 75% of the seropositive cases had either extrapulmonary or disseminated TB (DTB) whereas only 25% had the pulmonary variety of the disease. None of the seropositive cases had hemoptysis. Seroprevalence was 12.5% among patients complaining of breathlessness (OR = 2.03, *P* = 0.394). 6.59% of patients complaining of fever were seropositive (OR = 0.25, *P* = 0.152). Only 35% of patients complained of significant weight loss but again all the seropositive cases in our study had this complaint and seroprevalence was 22.86% (OR = 19.25, *P* = 0.000). Patients with symptoms of seizures, headache, meningeal irritation, and gastrointestinal disturbances did not have any significant association with seroprevalence. Among patients who gave a history of contact with a commercial sex worker, there was a high seroprevalence of 70% (OR = 207.67, *P* = 0.000).

Patients had a wide spectrum of clinical signs on examination \[[Table 5](#t5-jtim-2015-0017){ref-type="table"}\]. 26.08% of patients with lymphadenopathy were seropositive (OR = 13.24, *P* = 0.002). Oral candidiasis was seen in eight of our patients and 62.5% of them were seropositive (OR = 49.44, *P* = 0.000). Clinical findings on respiratory system examination were quite common and seroprevalence was 13.46% (OR = 7.31, *P* = 0.061). Seroprevalence was 36.36% among patients with signs on abdominal examination (OR = 12.14, *P* = 0.005). Pallor, jaundice, clubbing, edema, skin infections, and neurological signs did not have any statistically significant association with seropositivity.

Nourishment was poor in most of the subjects of our study. Seropositive patients were significantly undernourished when compared to seronegative patients (BMI 18.01 ±1.91 vs. 20.57 ± 2.66 kg/m^2^, *P* = 0.009). The Hb percentage was significantly lower in seropositive patients (8.64 ± 1.07 g%) than in seronegative patients (9.89 ± 1.73 g%, *P* = 0.047). Total leukocyte count was significantly lower in seropositive patients (5512.50 ± 1241.47 cells/ml) than in seronegative patients (1111.52 ± 2252.18 cells/ml, *P* = 0.000). 87.5% of all seropositive cases had bilateral chest radiograph involvement. 41.17% of all patients with bilateral chest radiograph involvement were seropositive (OR = 57.40, *P* = 0.000) \[[Table 6](#t6-jtim-2015-0017){ref-type="table"}\]. 28.57% of patients with bilateral parenchymal infiltration or consolidation were found to be seropositive (OR = 5.80, *P* = 0.096), however, there were none among those with unilateral parenchymal infiltration or consolidation. None of the seropositive cases had evidence of fibrosis, cavity or fibrocavity radiographically. All the patients with a reticulonodular pattern were seropositive (OR = 55.50, *P* = 0.000). Seroprevalence was 25% among those with miliary mottling (OR = 4.24, *P* = 0.287).

About 52% of cases in our study were of PTB but only 3.85% were seropositive (OR = 0.28, *P* = 0.149) \[[Table 7](#t7-jtim-2015-0017){ref-type="table"}\]. 4.88% of extra-pulmonary tuberculosis (EPTB) cases were seropositive (OR = 0.44, *P* = 0.466). Among the EPTB cases 12.5% of abdominal tuberculosis (OR = 4.24, *P* = 0.287) and 50% of tubercular meningitis (OR = 0.63, *P* \> 0.05) cases were seropositive. 37.5% of all the seropositive patients were diagnosed with DTB/milliary TB. Among the sputum positive PTB patients seroprevalence was 2.22% (OR = 0.16, *P* = 0.070) and among the sputum negative patients there were no seropositive patients. However among DTB/miliary TB patients seroprevalence was 66.67% (OR = 30.33, *P* = 0.016) and 50% (OR = 15.00, *P* = 0.031) among sputum positive and sputum negative patients, respectively. Seroprevalence was 10.14% and 4.76% among RNTCP Category I and II patients, respectively.

In Tamil Nadu, seroprevalence of HIV among TB was reported at 4.7% with the highest seropositivity rate among patients aged 30--39 years at 10.6% during 2008--2009 92% of the cases were found in the age group between 20 and 49.^\[[@b9-jtim-2015-0017]\]^ In Delhi seroprevalence increased from 0.4% in 1994--1999 to 8.4% in 2008--2009.^\[[@b10-jtim-2015-0017]\]^ Sentinel surveillance done in Pune showed that seropositivity has increased from 10% in 1995 to 20.75% in 2010.^\[[@b11-jtim-2015-0017]\]^ In Thanjavur, seroprevalence was seen to increase from 0.59% in the year 1996 to 8.89% in 2008.^\[[@b12-jtim-2015-0017]\]^ Seroprevalence in Goa was reported to increase from 2.01% in 1995 to 6.9% in 2009.^\[[@b13-jtim-2015-0017]\]^ Studies have shown that seroprevalence has increased from 2.6% in 1995--1996 to 11.7% in 2005--2006 in Mumbai.^\[[@b14-jtim-2015-0017]\]^

CONCLUSIONS
===========

Seroprevalence of HIV among TB was found to be 8% in our study. The highest rates of seropositivity were between the ages of 31--40 years. Our study suggests male TB patients aged between 21 and 40 years should be targeted as they account for the majority of the cases. Patients of certain high-risk occupations and behavior should be screened.

Seropositive TB patients commonly present with weight loss. On examination, severe anemia, undernourishment, lymphadenopathy, and presence of opportunistic infections like oral candidiasis are quite common. Radiologically, bilateral involvement and atypical features are hallmarks of a dual infection. Seropositive patients also have a much higher chance of DTB.

Hence, taking all of this into consideration clinicians should maintain a high index of suspicion and is imperative to have a thorough understanding of the interactions between these two diseases.
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###### 

Age and gender distribution in TB patients

  Age in years   Male (*n* = 81)   Female (*n* = 19)   Total (*n* = 100)           
  -------------- ----------------- ------------------- ------------------- ------- ----------------
  15--20         3                 3.70                ---                 ---     3
  21--30         19 (2, 10.5%)     23.46               5 (1, 20%)          26.31   24 (3, 12.5%)
  31--40         13 (5, 38.46%)    16.05               4                   21.05   17 (5, 29.41%)
  41--50         22                27.16               5                   26.32   27
  51--60         16                19.75               4                   21.05   20
  \>60           8                 9.87                1                   5.26    9
  Mean age       43.12±13.85                           41.32±12.82                 42.78±13.61

OR numbers in parenthesis are seropositive TB patients, followed by the percentage. TB: Tuberculosis, OR: Odds ratio

###### 

HIV seroprevalence among TB patients according to gender

  Gender    HIV+   HIV−   Total           
  --------- ------ ------ ------- ------- -----
  Male      7      8.64   74      91.36   81
  Female    1      5.26   18      94.74   19
  Overall   8      8.00   92      92.00   100

TB: Tuberculosis, HIV: Human immunodeficiency virus

###### 

HIV seroprevalence among TB patients according to occupation

  Occupation               HIV+   HIV−    Total            
  ------------------------ ------ ------- ------- -------- ----
  Agriculturist            4      13.79   25      86.21    29
  Service (clerk/tailor)   1      14.29   6       85.71    7
  Drivers                  1      25.00   3       75.00    4
  Housewives               1      5.88    16      94.12    17
  Laborers                 1      3.03    32      96.96    33
  Others                   ---            10      100.00   10

TB: Tuberculosis, HIV: Human immunodeficiency virus

###### 

Association of symptoms with seroprevalence in TB patients

  Symptoms                  HIV+   HIV−    Total   *P*      OR (HIV+)                                                            
  ------------------------- ------ ------- ------- -------- ----------- -------------------------------------------------------- --------
  Cough                     3      3.70    78      96.30    81          0.006[\*\*](#tfn5-jtim-2015-0017){ref-type="table-fn"}   0.11
  Hemoptysis                ---    ---     17      100.00   17          0.345                                                    ---
  Breathlessness            3      12.50   21      87.50    24          0.394                                                    2.03
  Fever                     6      6.59    85      93.41    91          0.152                                                    0.25
  Constitutional symptoms   8      10.96   65      89.04    73          0.104                                                    3.32
  Significant weight loss   8      22.86   27      77.14    35          0.000[\*\*](#tfn5-jtim-2015-0017){ref-type="table-fn"}   19.25
  Seizures                  2      18.18   9       81.82    11          0.213                                                    3.07
  Headache                  1      25.00   3       75.00    4           0.287                                                    4.24
  Altered sensorium         ---            9       100.00   9           \>0.05                                                   ---
  Symptoms of MI            2      16.67   10      83.33    12          0.253                                                    2.65
  Neck swelling             ---    ---     4       100.00   4           \>0.05                                                   ---
  GI symptoms               1      25.00   3       75.00    4           0.287                                                    4.24
  CSW                       7      70.00   3       30.00    10          0.000[\*\*](#tfn5-jtim-2015-0017){ref-type="table-fn"}   207.67

Statistical significance at 5%,

Statistical significance at 1%,

Near statistical significance.

TB: Tuberculosis, OR: Odds ratio, HIV: Human immunodeficiency virus, MI: Myocardial infarction, GI: Gastrointestinal, CSW: Commercial sex worker

###### 

Association of signs with seroprevalence in TB patients

  Signs               HIV+   HIV−    Total   *P*     OR (HIV+)                                                            
  ------------------- ------ ------- ------- ------- ----------- -------------------------------------------------------- -------
  Pallor              6      10.71   50      89.29   56          0.460                                                    2.52
  Jaundice            1      20.00   4       80.00   5           0.347                                                    3.14
  Clubbing            4      12.12   29      87.88   33          0.434                                                    2.17
  Edema               1      33.33   2       66.67   3           0.223                                                    6.43
  Skin infections     1      14.29   6       85.71   7           0.453                                                    2.05
  Lymphadenopathy     6      26.08   17      73.91   23          0.002[\*\*](#tfn9-jtim-2015-0017){ref-type="table-fn"}   13.24
  Oral thrush         5      62.50   3       37.50   8           0.000[\*\*](#tfn9-jtim-2015-0017){ref-type="table-fn"}   49.44
  Respiratory signs   7      13.46   45      86.54   52          0.061                                                    7.31
  Abdominal signs     4      36.36   7       63.64   11          0.005                                                    12.14
  CNS signs           3      15.00   17      85.00   20          0.196                                                    2.65

Statistical significance at 5%,

Statistical significance at 1%,

near statistical significance.

TB: Tuberculosis, OR: Odds ratio, HIV: Human immunodeficiency virus, CNS: Central nervous system

###### 

Association of chest X-ray findings with seroprevalence in TB patients

  Chest X-ray findings   HIV+   HIV−     Total   Significance (*P* value by χ^2^ or Fisher's exact test)   OR (HIV+)                                                             
  ---------------------- ------ -------- ------- --------------------------------------------------------- ----------- --------------------------------------------------------- --------
  UL investigation       1      1.96     50      98.04                                                     51          0.029[\*](#tfn12-jtim-2015-0017){ref-type="table-fn"}     0.12
  BL investigation       7      41.17    10      58.82                                                     17          0.000[\*\*](#tfn13-jtim-2015-0017){ref-type="table-fn"}   57.40
  UL (C/FC/F)            ---    ---      10      100.00                                                    10          \>0.05                                                    ---
  BL (C/FC/F)            ---    ---      1       100.00                                                    1           \>0.05                                                    ---
  UL (Infil/CO)          ---    ---      31      100.00                                                    31          0.055[a](#tfn14-jtim-2015-0017){ref-type="table-fn"}      ---
  BL (Infil/CO)          2      28.57    5       71.43                                                     7           0.096[a](#tfn14-jtim-2015-0017){ref-type="table-fn"}      5.80
  UL PE                  1      5.00     19      95.00                                                     20          \>0.05                                                    0.55
  BL PE                  ---    ---      ---     ---                                                       ---         ---                                                       ---
  RP                     3      100.00   ---     ---                                                       3           0.000[\*\*](#tfn13-jtim-2015-0017){ref-type="table-fn"}   ≈55.20
  MM                     1      25.00    3       75.00                                                     4           0.287                                                     4.24

Statistical significance at 5%,

Statistical significance at 1%,

Near statistical significance.

UL: Unilateral, BL: Bilateral, F: Fibrosis/fibrothorax, C: Cavitation, FC: Fibrocavity, CO: Consolidation, Infil: Infiltration, PE: Pleural effusion, RP: Reticulonodular pattern, MM: Miliary mottling, OR: Odds ratio, TB: Tuberculosis, HIV: Human immunodeficiency virus

###### 

Association of diagnosis with seroprevalence in TB patients

  Diagnosis   HIV+   HIV−    Total   *P*      OR (HIV+)                                                             
  ----------- ------ ------- ------- -------- ----------- --------------------------------------------------------- -------
  PTB         2      3.85    50      96.15    52          0.149                                                     0.28
  PTB Sp+     1      2.22    44      97.78    45          0.070[\*](#tfn16-jtim-2015-0017){ref-type="table-fn"}     ---
  PTB Sp−     ---    ---     7       100.00   14          0.596                                                     ---
  EPTB        2      4.88    39      96.12    41          0.466                                                     0.44
  EPTB PE     ---    ---     14      100.00   14          0.596                                                     ---
  EPTB TBL    ---    ---     4       100.00   4           0.895                                                     ---
  EPTB ABTB   1      25      3       75       4           0.287                                                     4.24
  EPTB TBM    1      5.56    17      94.44    18          0.985                                                     0.63
  EPTB TBS    ---    ---     1       100.00   1           0.876                                                     ---
  DTB/MTB     4      57.14   3       42.86    7           0.001[\*\*](#tfn17-jtim-2015-0017){ref-type="table-fn"}   29.67
  DTB Sp+     2      66.67   1       33.33    3           0.016[\*](#tfn16-jtim-2015-0017){ref-type="table-fn"}     30.33
  DTB Sp−     2      50.00   2       50.00    4           0.031[\*](#tfn16-jtim-2015-0017){ref-type="table-fn"}     15.01

Statistical significance at 5%,

Statistical significance at 1%,

Near statistical significance.

PTB: Pulmonary tuberculosis, EPTB: Extra pulmonary tuberculosis, PE: Pleural effusion, TBL: Tubercular lymphadenopathy, ABTB: Abdominal tuberculosis, TBM: Tubercular meningitis, TBS: Tuberculosis spine, DTB: Disseminated tuberculosis, MTB: Miliary tuberculosis, Sp+: Sputum positive, Sp−: Sputum negative, TB: Tuberculosis, HIV: Human immunodeficiency virus, OR: Odds ratio
